PILL241220C11000
- 0.00
- 0.000.00%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares Newsroom
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's...
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target
Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who...
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
BofA Restarts Coverage of 11 Large-cap Biopharmas
Jazz Pharmaceuticals Analyst Ratings
B of A Securities Reinstates Neutral on Bristol-Myers Squibb, Announces $63 Price Target
Bristol-Myers Squibb Analyst Ratings
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
The WuXi system welcomes a bullish trend! What is the next catalyst?
Many institutions have indicated that this may be a critical juncture for the healthcare sector.
President Elect Trump Said He Will Not Restrict The Availability Of Abortion Pills -NBC's Meet The Press
Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex Benefits And Broad-Spectrum Efficacy In Treatment-Resistant Epilepsies At AES 2024 Annual Meeting
Viatris Analyst Ratings
Catalent Gains Amid Report Buyer Working on Contact Extensions With Drugmakers
Jazz Pharmaceuticals To Present Advancements In Solid Tumors And Blood Cancer Research At San Antonio Breast Cancer Symposium And American Society Of Hematology Annual Meeting From December 7-10
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.